What does it really mean to heal? To find strength in uncertainty? To not just survive, but thrive?
Welcome to Rubin on Point. I’m Dr. Dan Rubin, a naturopathic oncologist exploring the science—and soul—of resilience.
This podcast is about how we heal, adapt, and harness our inner strength. Through conversations with experts, survivors, and innovators, we’ll uncover how people redefine health and transform their lives—no matter the challenge. Let’s get started.
Cancer isn’t just about mutations.
In Part 2 of this conversation, Dr. Brandon Guida breaks down how epigenomics is transforming the way we detect, monitor, and understand cancer in real time.
If Part 1 explained the “operating system,” this episode shows how that system becomes a fingerprint for disease—and how we can actually measure it.
We dive into:
- How epigenomic patterns create a detectable cancer signature
- The difference between ctDNA vs cfDNA
- Why methylation increases sensitivity in cancer detection
- How tumors evolve (and why treatment can stop working)
- What tumor fraction really means—and why it matters
- The clinical gap: why this data isn’t used enough (yet)
This is where diagnostics meet precision medicine.
And where the future of oncology is heading.
⏱️ CHAPTERS
00:00 – Welcome back + Part 1 recap
00:52 – Epigenomics in cancer: what changes
53:31 – Cancer “fingerprints” explained
54:29 – Multi-cancer early detection tests
55:14 – ctDNA vs cfDNA (the “haystack” analogy)
57:20 – The future: multi-modal diagnostics
58:04 – Why epigenomics improves detection sensitivity
01:00:11 – Mutations vs epigenetic changes
01:01:20 – Why methylation gives more signal
01:02:32 – BRCA: mutation vs epigenetic silencing
01:04:09 – Why testing matters (if you’re looking for it)
01:07:18 – Tp53 explained (and why it’s a big deal)
01:13:58 – Clonal evolution + treatment resistance
01:15:50 – Tumor fraction: how it’s calculated
01:16:52 – When treatment looks like it’s working—but isn’t
01:18:10 – Why clinicians aren’t using this enough (yet)